Oncology ASCO 2024 - Paul Burton For Amgen, ASCO 2024 was all about lung cancer, with encouraging data in both non-small cell and small cell lung cancer.
News Madrigal builds in MASH with $4.4bn+ Ribo alliance Already sitting on a blockbuster therapy for MASH, Madrigal has beefed up its pipeline with six siRNA candidates licensed from China's Ribo.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
